

Iowa Medicaid Drug Utilization Review (DUR) Commission

November 5, 2025

Meeting Format: Virtual

Time: 9:30 a.m. – 1:30 p.m.

Teams Meeting: https://teams.microsoft.com/l/meetup-join/19%3ameeting_MTMyMjBIZDgtMTU2ZC00ODJkLWE1OGUtYjQ1YWI2YTU2MTY0%40thread.v2/0?context=%7b%22Tid%22%3a%228d2c7b4d-085a-4617-8536-38a76d19b0da%22%2c%22Oid%22%3a%22982a0572-2333-4ea7-b2e0-b02af2367c61%22%7d

Meeting ID: 230 635 810 165 6

Passcode: dj9H3Uw9

Tentative Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of August 6, 2025 Meeting Minutes
 - b) August 2025 DUR Recommendation Letter to DHHS
 - c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
 - a) Iowa Total Care
 - b) Molina Healthcare of Iowa
 - c) Wellpoint Iowa
 - d) Fee-for-Service
 - e) Comparative Summary
5. Public Comment* (Complete [Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. Must indicate if will be in-person or verbal testimony. Five (5) minute maximum limit.
 - Written – Must submit written comments and a completed conflict of interest disclosure,
 - **All submissions must be received no later than 4:30 p.m. CT October 29, 2025.**
 - **Send to pba_iadur@optum.com. Indicate in email if providing written or verbal comment.**
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Risk of Hyperthermia with Scopolamine Patch
 - ii. Utilization of SGLT2 Inhibitors in Members with CKD
 - b) Proposal(s)
 - i. Duplicate Short-Acting Opioids
 - ii. Bisphosphonate Drug Holiday
 - c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)
8. Prior Authorization

- a) Annual Review of Prior Authorization Criteria
 - b) Brenoscatib (Brinsupri)
 - c) Diazoxide Choline (Vykat XR)
 - d) Hepatitis C Treatments, Direct Acting Antivirals
 - e) Incretin Mimetics for Non-Diabetes Indications
 - f) Janus Kinase Inhibitors
 - g) Pegcetacoplan (Empaveli)
 - h) Sepiaptern (Sephience)
 - i) Select Topical Agents
9. Miscellaneous
- a) DUR Digest Vol. 38, No. 1 – First Review
10. MedWatch
- [FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’](#)
 - [FDA Approves Medication to Treat 2 Rare Diseases that Can Lead to Kidney Failure](#)
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay of your comments being considered until the next scheduled meeting. Reference complete public comment policy [here](#).

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
February 4, 2026
Meeting Format: Virtual